Page 57 - Haematologica Vol. 109 - July 2024

REVIEW ARTICLE - CXCL8 in primary myelofibrosis
G. Vermeersch et al.
48. Cambier S, Gouwy M, Proost P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. Cell Mol Immunol. 2023;20(3):217-251.
49. Yang L, Herrera J, Gilbertsen A, et al. IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol. 2018;314(1):L127-L136.
50. Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med. 1988;167(6):1883-1893.
51. Schröder JM, Sticherling M, Henneicke HH, Preissner WC, Christophers E. IL-1 alpha or tumor necrosis factor-alpha stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts. J Immunol. 1990;144(6):2223-2232.
52. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96(8):2673-2681.
53. Mortier A, Berghmans N, Ronsse I, et al. Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PloS One. 2011;6(8):e23913.
54. Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol. 2009;183(5):3425-3432.
55. Liu K, Wu L, Yuan S, et al. Structural basis of CXC chemokine receptor 2 activation and signalling. Nature. 2020;585(7823):135-140.
56. Ishimoto N, Park JH, Kawakami K, et al. Structural basis of CXC chemokine receptor 1 ligand binding and activation. Nat Commun. 2023;14(1):4107.
57. Teijeira Á, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856-871.
58. Alfaro C, Teijeira A, Oñate C, et al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin Cancer Res. 2016;22(15):3924-3936.
59. Yalavarthi S, Gould TJ, Rao AN, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015;67(11):2990-3003.
60. Van Alsten SC, Aversa JG, Santo L, et al. Association between ABO and Duffy blood types and circulating chemokines and cytokines. Genes Immun. 2021;22(3):161-171.
61. Jinna N, Rida P, Su T, et al. The DARC side of inflamm-aging: Duffy antigen receptor for chemokines (DARC/ACKR1) as a potential biomarker of aging, immunosenescence, and breast oncogenesis among high-risk subpopulations. Cells. 2022;11(23):3818.
62. Peseski AM, Saliba AN, Althouse SK, Sayar H. Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms? Hematol Oncol Stem Cell Ther. 2022;15(2):30-38.
63. Fan X, Patera AC, Pong-Kennedy A, et al. Murine CXCR1 Is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem. 2007;282(16):11658-11666.
64. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
65. Øbro NF, Grinfeld J, Belmonte M, et al. Longitudinal cytokine profiling identifies GRO-α and EGF as potential biomarkers of disease progression in essential thrombocythemia. Hemasphere. 2020;4(3):e371.
66. Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2005;105(2):464-473.
67. Daly TJ, LaRosa GJ, Dolich S, Maione TE, Cooper S, Broxmeyer HE. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. J Biol Chem. 1995;270(40):23282-23292.
68. Broxmeyer HE, Cooper S, Cacalano G, Hague NL, Bailish E, Moore MW. Involvement of interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue. J Exp Med. 1996;184(5):1825-1832.
69. Sanchez X, Suetomi K, Cousins-Hodges B, Horton JK, Navarro J. CXC chemokines suppress proliferation of myeloid progenitor cells by activation of the CXC chemokine receptor 2. J Immunol. 1998;160(2):906-910.
70. Adeli EK, Abolghasemi H, Ebtekar M, Pourpak Z, Kheirandish M. Effects of CXCR1 and CXCR2 inhibition on expansion and differentiation of umbilical cord blood CD133(+) cells into megakaryocyte progenitor cells. Cytokine. 2011;55(2):181-187.
71. Gewirtz AM, Zhang J, Ratajczak J, et al. Chemokine regulation of human megakaryocytopoiesis. Blood. 1995;86(7):2559-2567.
72. Binder V, Li W, Faisal M, et al. Microenvironmental control of
hematopoietic stem cell fate via CXCL8 and protein kinase C.
Cell Rep. 2023;42(5):112528.
73. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J. Synergy
between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. J Leukoc Biol. 2004;76(1):185-194.
74. Nesmelova IV, Sham Y, Dudek AZ, et al. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem. 2005;280(6):4948-4958.
75. Dudek AZ, Nesmelova I, Mayo K, Verfaillie CM, Pitchford S, Slungaard A. Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesis. Blood. 2003;101(12):4687-4694.
76. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood. 2008;112(8):3026-3035.
77. Brouty-Boyé D, Briard D, Azzarone B, et al. Effects of human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues on CD34+ stem cells. Int J Cancer. 2001;92(4):484-488.
78. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol. 2008;15(1):49-58.
79. Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol. 2009;146(2):150-157.
Haematologica | 109 July 2024
2071